Davergne, Thomas http://orcid.org/0000-0001-7869-0062
Tekaya, Rawdha
Sellam, Jérémie
Tournadre, Anne
Mitrovic, Stéphane
Ruyssen-Witrand, Adeline
Hudry, Christophe
Dadoun, Sabrina
Avouac, Jérôme
Fautrel, Bruno
Gossec, Laure
Funding for this research was provided by:
Eli Lilly and Company
Sandoz
Article History
Received: 27 April 2021
Accepted: 15 October 2021
First Online: 30 October 2021
Declarations
:
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards<b>.</b> The validation study was accepted by the ethics committee (CPP Sud-Est III, France, EudraCT 2019-A01413-54, methodology MR03 for non-interventional study). Informed consent was obtained from all individual participants included in the study.
: Not applicable.
: Thomas Davergne, Rawdha Tekaya, Camille Deprouw, Jérémie Sellam, Anne Tournadre, Stéphane Mitrovic, Adeline Ruyssen-Witrand, Christophe Hudry, Sabrina Dadoun, Jérôme Avouac, Laure Gossec declare that they have no relevant disclosures. Bruno Fautrel has received research grants from AbbVie, Lilly, MSD and Pfizer, and consultancy fees from AbbVie, Amgen, Biogen, BMS, Celgene, Celltrion, Fresenius Kabi, Gilead, Janssen, Lilly, Medac, MSD, Mylan, NORDIC Pharma, Novartis, Pfizer, Roche, Sandoz, Sanofi-Genzyme, SOBI, UCB.